Balaxi Pharmaceuticals (NSE:BALAXI), a Hyderabad-based pharmaceutical company, filed an intimation on 14 August 2026 under Regulation 30 of the SEBI LODR Regulations, enclosing copies of newspaper advertisements published in Business Standard and Nava Telangana regarding SEBI's Special Window for Transfer and Dematerialisation of Physical Shares.
Key Highlights
- Balaxi Pharmaceuticals published newspaper notices on 14 August 2026 in Business Standard (English) and Nava Telangana (Telugu) about the SEBI special demat window.
- The Special Window, opened pursuant to SEBI Circular No. HO/38/13/11(2)2026-MIRSD-POD/I/3750/2026 dated 30 January 2026, runs from 5 February 2026 to 4 February 2027.
- The window covers transfer and dematerialisation requests for physical shares that were sold or purchased prior to 1 April 2019, including previously rejected or unattended requests.
- Securities transferred under this window will be issued in demat form only and will carry a one-year lock-in from the date of registration of transfer.
About the Company
Balaxi Pharmaceuticals Limited is a Hyderabad-based company incorporated in 1942 and listed on the NSE under the ticker BALAXI. The company operates in the pharmaceuticals sector, with its registered office at Maps Towers, Jubilee Hills, Hyderabad, Telangana. It carries out pharmaceutical trading and related activities, with a CIN of L25191TG1942PLC121598.
Announcement in Detail
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Balaxi Pharmaceuticals filed an intimation on 14 August 2026 enclosing newspaper advertisements published in Business Standard and Nava Telangana. The advertisements inform shareholders about SEBI's Special Window for Transfer and Dematerialisation of Physical Shares, operative from 5 February 2026 to 4 February 2027.
The window permits lodgement or re-lodgement of transfer and demat requests for physical shares transacted before 1 April 2019, including requests that were previously rejected, returned, or left unattended due to document or process deficiencies. Cases involving disputes between transferor and transferee, or shares already transferred to the Investor Education and Protection Fund, are explicitly excluded from this window's scope.
Impact on Investors
Investors will note that shareholders of Balaxi Pharmaceuticals who hold physical shares acquired or sold before 1 April 2019 now have a defined deadline of 4 February 2027 to lodge or re-lodge transfer and dematerialisation requests under this SEBI-facilitated window. The filing shows that securities transferred under this mechanism will be issued exclusively in demat form and will be subject to a one-year lock-in period commencing from the date of registration of transfer, which shareholders should factor into their planning.
The disclosed terms indicate that this is a compliance-driven communication and does not alter the company's capital structure, financials, or shareholding pattern. It does not dilute existing shareholders or create new securities.
Sector / Market Context
SEBI's initiative to facilitate transfer and dematerialisation of legacy physical securities reflects a broader regulatory push to improve investor protection and reduce the volume of unclaimed or unresolved physical share holdings in the Indian market. According to SEBI disclosures, a significant number of transfer requests predating the April 2019 mandatory demat requirement remained pending or rejected, prompting this one-year special window announced in January 2026. Pharmaceutical companies such as Balaxi Pharmaceuticals are among several listed entities publishing such mandatory notices in compliance with SEBI's circular directives during this window period.